TNFRSF8 and Hodgkins lymphoma: Complete remission rates of 50%-65% were achieved using PD-1 monoclonal antibody nivolumab in combination with brentuximab vedotin, an ADC drug targeting CD30, for refractory relapsed Hodgkin’s lymphoma (49).